These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
91 related articles for article (PubMed ID: 165029)
21. Treatment of hyperlipoproteinemias with neomycin, probucol and tibric acid. Miettinen TA Adv Exp Med Biol; 1977; 82():483-8. PubMed ID: 920404 [No Abstract] [Full Text] [Related]
22. Evaluation of the Effects of Cucumis sativus Seed Extract on Serum Lipids in Adult Hyperlipidemic Patients: A Randomized Double-Blind Placebo-Controlled Clinical Trial. Soltani R; Hashemi M; Farazmand A; Asghari G; Heshmat-Ghahdarijani K; Kharazmkia A; Ghanadian SM J Food Sci; 2017 Jan; 82(1):214-218. PubMed ID: 27886382 [TBL] [Abstract][Full Text] [Related]
23. Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome. Vega GL; Cater NB; Hadizadeh DR; Meguro S; Grundy SM Clin Pharmacol Ther; 2003 Sep; 74(3):236-44. PubMed ID: 12966367 [TBL] [Abstract][Full Text] [Related]
24. Effect of primrose oil on serum lipids and blood pressure in hyperlipidemic subjects. Viikari J; Lehtonen A Int J Clin Pharmacol Ther Toxicol; 1986 Dec; 24(12):668-70. PubMed ID: 3028968 [TBL] [Abstract][Full Text] [Related]
25. Effect of tibric acid on hepatic cholesterol synthesis in rats. Cayen MN; Dubuc J; Dvornik D Lipids; 1977 Aug; 12(8):684-8. PubMed ID: 895418 [TBL] [Abstract][Full Text] [Related]
26. [Beta-sitosterin in unsuccessfully pretreated patients with hypercholesteremia. Simultaneously, a contribution to dose dependence]. Mühlfellner G; Mühlfellner O; Kaffarnik H Med Klin; 1976 Apr; 71(18):775-8. PubMed ID: 178987 [TBL] [Abstract][Full Text] [Related]
27. [Hypolipidemic effect of cholestyramine in patients affected by type II hyperlipoproteinemia]. Sauvanet JP; Drouin P; Mejean L; Lambert D; Debry G Therapie; 1978; 33(5):615-22. PubMed ID: 217121 [No Abstract] [Full Text] [Related]
28. Treatment of primary hyperlipoproteinaemias with a tetralin derivative (Su-13'437). Fellin R; Fedele D; Bagnariol G; Pagnan A; Crepaldi G Atherosclerosis; 1973; 17(3):383-8. PubMed ID: 4577009 [No Abstract] [Full Text] [Related]
29. [Determination of the dose-response curve of a new hypolipidemic molecule: tibric acid (CP-18524). Methodologic and statistical aspects]. Bielmann P; Annable L; Brun D; Moorjani S; Lupien PJ; Tétreault L Union Med Can; 1975 Jun; 104(6):930-4. PubMed ID: 1224412 [No Abstract] [Full Text] [Related]
30. Effects of a new fish oil concentrate on plasma lipids and lipoproteins in patients with hypertriglyceridaemia. Mackness MI; Bhatnagar D; Durrington PN; Prais H; Haynes B; Morgan J; Borthwick L Eur J Clin Nutr; 1994 Dec; 48(12):859-65. PubMed ID: 7889894 [TBL] [Abstract][Full Text] [Related]
31. [Treatment of hyperlipidemia with a new drug, tibric acid]. Carmena R; González R Florez J; Sanchis J Rev Clin Esp; 1976 Jul; 142(2):151-5. PubMed ID: 788065 [No Abstract] [Full Text] [Related]
32. [Hypolipidemic activity of substances structurally close to penphenone in rats and mice]. Polikarpova LI; Reznik SE; Ryzhenkov VV; Khechinashvili GG; Petrova LA Vopr Med Khim; 1978; 24(6):835-9. PubMed ID: 216145 [TBL] [Abstract][Full Text] [Related]
33. An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia. Durrington PN; Bhatnagar D; Mackness MI; Morgan J; Julier K; Khan MA; France M Heart; 2001 May; 85(5):544-8. PubMed ID: 11303007 [TBL] [Abstract][Full Text] [Related]
34. Atilipidemic drugs. Part 5: Evaluation of the hypolipidemic effect of LF 178 in 191 patients affected by the atherogenic form of endogenous hyperlipoproteinemia (types IIa, IIb and IV). Rouffy J; Dreux C; Goussault Y; Dakkak R; Renson FJ Arzneimittelforschung; 1976; 26(5):901-6. PubMed ID: 183788 [TBL] [Abstract][Full Text] [Related]
35. Gemfibrozil: effect on serum lipids, lipoproteins, postheparin plasma lipase activities and glucose tolerance in primary hypertriglyceridaemia. Nikkilä EA; Ylikahri R; Huttunen JK Proc R Soc Med; 1976; 69 Suppl 2(Suppl 2):58-63. PubMed ID: 190608 [TBL] [Abstract][Full Text] [Related]
36. [Treatment of primary hyperlipoproteinemias of type IIB and IV with butylbiguanide and clofibrate (author's transl)]. Koschinsky T; Gries FA; Schwandt P; Weisweiler P; Hansen W; Nijssen J; Beckmann R MMW Munch Med Wochenschr; 1977 May; 119(20):701-4. PubMed ID: 195201 [TBL] [Abstract][Full Text] [Related]
38. [Therapy of hyperlipoproteinemia type II with Xantinol-nicotinate (author's transl)]. Haacke H; Parwaresch MR; Mäder C Med Klin; 1977 Jul; 72(27):1183-7. PubMed ID: 196168 [TBL] [Abstract][Full Text] [Related]
39. [Sitosterol in familial hyperlipoproteinemia type II. A randomized double-blind cross-over study]. Oster P; Schlierf G; Heuck CC; Greten H; Gundert-Remy U; Haase W; Klose G; Nothelfer A; Raetzer H; Schellenberg B; Schmidt-Gayk H Dtsch Med Wochenschr; 1976 Sep; 101(36):1308-11. PubMed ID: 182445 [TBL] [Abstract][Full Text] [Related]
40. [Comparison of clofibrate and bezafibrate in type IIa and type IIb hyperlipoproteinemia]. Arntz HR; Klemens UH; Vollmar LJ; Lang PD Med Klin; 1978 Dec; 73(49):1731-7. PubMed ID: 723760 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]